share_log

American Public Education Sees FY24 Revenue $620M-$625M Vs $622.52M Estimate

American Public Education Sees FY24 Revenue $620M-$625M Vs $622.52M Estimate

美國公共教育公司預計FY24年營業收入爲62000萬美元。達到62500萬美元,超過62252萬美元的預估
Benzinga ·  2024/11/13 05:21

Fourth Quarter and Full Year 2024 Outlook

2024年第四季度和全年展望

The following statements are based on APEI's current expectations. These statements are forward-looking and actual results may differ materially. APEI undertakes no obligation to update publicly any forward-looking statements for any reason unless required by law. Refer to APEI's earnings conference call and presentation for further details.

以下陳述基於APEI目前的預期。這些陳述屬於前瞻性聲明,實際結果可能有重大差異。除非法律要求,否則APEI不承擔更新任何前瞻性聲明的公共義務。請參考APEI的業績會議通話和陳述以獲取更多詳情。


Fourth Quarter 2024 Guidance

(Approximate) (% Yr/Yr Change)
APUS Net course registrations 94,400 to 96,100 4% to 6%
HCN Student enrollment 3,700 19 %
RU Student enrollment 14,600 4 %
- On-ground Healthcare 6,300 -3 %
- Online 8,300 9 %



($ in millions except EPS)

APEI Consolidated revenue $159.0 – $164.0 4% to 8%
APEI Net loss/income available to common stockholders $9.0 – $11.0 (20%) – (4.0%)
APEI Adjusted EBITDA $23.0 – $26.0 (10%) to 2%
APEI Diluted EPS $0.47 – $0.56 (26%) to (13%)




Full Year 2024 Guidance

(Approximate) (% Yr/Yr Change)
($ in millions)

APEI Consolidated Revenue $620 – $625 3% to 4%
APEI Net income available to common stockholders $7-$9 n.m.
APEI Adjusted EBITDA $64 – $67 7% to 12%
APEI Capital Expenditure (CapEx) $19 – $22 37% to 58%

2024年第四季度展望

(近似值) (%年度/年度變化)
APUS淨課程註冊人數 94,400 到 96,100 上升4%至上升6%
hcn學生註冊 3700 19 %
RU學生註冊 14,600 4%
- 現場醫療服務 6,300 -3%
- 在線 8,300 9%



(單位爲百萬美元,除了每股收益)

APEI 綜合營業收入 $159.0 – $164.0 4%到8%
APEI普通股股東可獲得的淨虧損/收益 $9.0 – $11.0 (20%) – (4.0%)
APEI調整後的EBITDA $23.0 – $26.0 (10%)至2%
APEI攤薄後每股收益 $0.47 – $0.56 (26%)至(13%)




2024年全年指導

(近似值) (%年度/年度變化)
($ in millions)

APEI綜合營業收入 $620 – $625 3%至4%。
APEI普通股股東可得淨利潤 $7-$9 不適用
APEI調整後的EBITDA $64 – $67 7%至12%
APEI資本支出(CapEx) $19 – $22 37%至58%
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論